Alkermes (NASDAQ:ALKS) issued an update on its FY18 earnings guidance on Wednesday morning. The company provided earnings per share guidance of ($0.23-0.03) for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.73. The company issued revenue guidance of $975 million-1.025 billion, compared to the consensus revenue estimate of $1.01 billion.
Alkermes (NASDAQ ALKS) opened at $54.69 on Wednesday. Alkermes has a twelve month low of $46.42 and a twelve month high of $64.04. The company has a market capitalization of $8,513.03, a price-to-earnings ratio of -49.27 and a beta of 1.94. The company has a quick ratio of 2.72, a current ratio of 3.05 and a debt-to-equity ratio of 0.23.
Alkermes (NASDAQ:ALKS) last announced its earnings results on Wednesday, February 14th. The company reported $0.31 EPS for the quarter, topping the Zacks’ consensus estimate of $0.13 by $0.18. Alkermes had a negative return on equity of 7.27% and a negative net margin of 20.12%. The company had revenue of $275.37 million for the quarter, compared to analysts’ expectations of $251.23 million. During the same period last year, the firm earned $0.02 EPS. Alkermes’s revenue for the quarter was up 29.0% compared to the same quarter last year. analysts anticipate that Alkermes will post -0.59 earnings per share for the current year.
In other news, SVP Laurie Keating sold 6,249 shares of the firm’s stock in a transaction dated Wednesday, December 20th. The stock was sold at an average price of $121.20, for a total transaction of $757,378.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Shane Cooke sold 6,207 shares of the firm’s stock in a transaction dated Thursday, January 11th. The shares were sold at an average price of $60.22, for a total value of $373,785.54. Following the transaction, the insider now owns 80,915 shares of the company’s stock, valued at approximately $4,872,701.30. The disclosure for this sale can be found here. Over the last three months, insiders have sold 135,485 shares of company stock worth $8,227,502. Insiders own 5.34% of the company’s stock.
Alkermes Company Profile
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.